Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11849771 | 0.75 | ADRB2 (0.52) | KDM4EADRB1ADRB2ADRB3 | |
| SCHEMBL11852917 | 0.72 | ADRB2 (0.45) | GLAHTTNPSR1KDM4EADRB1 | |
| SCHEMBL15206556 | 0.71 | MEN1 (0.46) | GLAADRB1ADRB2CYP2D6NFKB1 | |
| SCHEMBL22864142 | 0.70 | ADRB2 (0.52) | KDM4EADRB1ADRB2 | |
| SCHEMBL166818 | 0.70 | KCNH2 (0.54) | GLAADRB1ADRB2CYP2D6NFKB1 | |
| SCHEMBL7147316 | 0.70 | KCNH2 (0.54) | GLAADRB1ADRB2CYP2D6NFKB1 | |
| SCHEMBL24630996 | 0.70 | LMNA (0.40) | KDM4EADRB1ADRB2SIGMAR1BCHE | |
| SCHEMBL10879222 | 0.70 | KDM4E (0.45) | KDM4EADRB1ADRB2SIGMAR1ADRB3 | |
| SCHEMBL22864136 | 0.70 | KDM4E (0.40) | KDM4EADRB1ADRB2SIGMAR1BCHE | |
| SCHEMBL13992547 | 0.69 | KDM4E (0.50) | GLAHTTNPSR1KDM4EADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515023-B2 | For inhibiting the aggregation of blood platelets; 3-(4-Aminomethyl-phenyl)-1-(2-(3,4-dichloro-phenyl)-2-hydroxy-ethyl)-1 -isopropyl-urea for example | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020007045-A1 | Thrombin receptor antagonists | MERCK & CO., INC. | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007045-A1 | Thrombin receptor antagonists | F2R, TBXA2R, PTAFR | GLA 1772/4885HTT 3264/4885NPSR1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.